BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
9/8/2016 10:53:00 AM | Browse: 901 | Download: 958
 |
Received |
|
2016-03-22 09:38 |
|
Peer-Review Started |
|
2016-03-22 16:43 |
|
To Make the First Decision |
|
2016-05-12 14:37 |
|
Return for Revision |
|
2016-05-12 15:33 |
|
Revised |
|
2016-07-11 02:57 |
|
Second Decision |
|
2016-07-18 08:58 |
|
Accepted by Journal Editor-in-Chief |
|
2016-07-18 18:48 |
|
Accepted by Company Editor-in-Chief |
|
2016-08-01 15:17 |
|
Articles in Press |
|
2016-08-01 15:17 |
 |
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2016-08-24 15:46 |
|
Publish the Manuscript Online |
|
2016-09-08 10:53 |
| ISSN |
1007-9327 (print) and 2219-2840 (online) |
| Open Access |
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2016. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Review |
| Article Title |
Recent advances in orally administered cell-specific nanotherapeutics for inflammatory bowel disease
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Xiao-Ying Si, Didier Merlin and Bo Xiao |
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| National Natural Science Foundation of China |
51503172 |
| National Natural Science Foundation of China |
81571807 |
| Fundamental Research Funds for the Central Universities |
SWU114086 |
| Fundamental Research Funds for the Central Universities |
XDJK2015C067 |
| Scientific Research Foundation for the Returned Overseas Chinese Scholars (State Education Ministry), the Department of Veterans Affairs |
|
| National Institutes of Health of Diabetes and Digestive and Kidney |
RO1-DK-071594 |
| Career Scientist Award from the Department of Veterans Affairs |
|
|
| Corresponding Author |
Bo Xiao, PhD, Institute for Clean Energy and Advanced Materials, Faculty of Materials and Energy, Southwest University, Tiansheng Road No. 2, Chongqing 400715, China. hustboxiao@gmail.com |
| Key Words |
Oral administration; Nanotherapeutic; Cell-specificity; Inflammatory bowel disease |
| Core Tip |
Inflammatory bowel disease includes Crohn’s disease and ulcerative colitis. Nanotherapeutics may outperform conventional medications via the targeted drug delivery, sustained drug release, and decreased adverse effect. The main purpose of this review is to offer an update of efficacy of the orally administrated cell-specific nanotherapeutics that have been developed recently. |
| Publish Date |
2016-09-08 10:53 |
| Citation |
Si XY, Merlin D, Xiao B. Recent advances in orally administered cell-specific nanotherapeutics for inflammatory bowel disease. World J Gastroenterol 2016; 22(34): 7718-7726 |
| URL |
http://www.wjgnet.com/1007-9327/full/v22/i34/7718.htm |
| DOI |
http://dx.doi.org/10.3748/wjg.v22.i34.7718 |
© 2004-2024 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
